The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 10, pp. 1448-1456. DOI 10.1345/aph.1D143
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duffalo, M. L
Right arrow Articles by James, C. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duffalo, M. L
Right arrow Articles by James, C. W

FORMULARY FORUM

Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection

Melody L Duffalo, PharmD

Clinical Pharmacist, Penn Community Infectious Diseases, Presbyterian Medical Center, Philadelphia, PA

Christopher W James, PharmD

Clinical Pharmacy Specialist, HIV Community Program, Christiana Care Health Services, Wilmington, DE

Reprints: Christopher W James PharmD, HIV Community Program, Christiana Care Health Services, PO Box 1668, Wilmington, DE 19899-1668, FAX 302/255-1374, cjames{at}christianacare.org

OBJECTIVE: To review the pharmacology, virology, pharmacokinetics, efficacy, safety, and clinical use of enfuvirtide.

DATA SOURCES: English-language MEDLINE and AIDSline searches were performed (1966-January 2003) using enfuvirtide, T-20, gp41, and fusion inhibitors as key words. Abstracts from infectious diseases and HIV scientific meetings were identified.

DATA EXTRACTION: All publications and meeting abstracts were reviewed and relevant items included. In vitro and preclinical studies were included, as well as Phase II and III clinical trials.

DATA SYNTHESIS: Enfuvirtide is a fusion inhibitor used for the treatment of HIV-1 infection. Given its unique mechanism of action, most HIV-1 isolates are susceptible to enfuvirtide. Enfuvirtide is administered by subcutaneous injection twice daily. In clinical trials with antiretroviral-experienced patients, enfuvirtide was effective at suppressing HIV-RNA and increasing CD4+ T-cell counts. Enfuvirtide should be used in combination with other active antiretroviral agents to optimize its efficacy and limit resistance. Injection site reactions associated with administration of the drug are experienced in the majority of patients. Availability of enfuvirtide may be limited by a complex manufacturing procedure.

CONCLUSIONS: Enfuvirtide is an effective treatment option for HIV-1-infected individuals when used in combination with other antiretroviral agents. It may be used as part of a regimen for treatment-experienced patients.

Key Words: enfuvirtide, fusion inhibitor, Fuzeon, HIV

Published Online, August 22, 2003. www.theannals.com, DOI 10.1345/aph.1D143

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-03-028-H02


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. Borras-Blasco, A. Navarro-Ruiz, C. Borras, and E. Castera
Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection
J. Antimicrob. Chemother., November 1, 2008; 62(5): 879 - 888.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.